Biofourmis Revenue and Competitors
Estimated Revenue & Valuation
- Biofourmis's estimated annual revenue is currently $117.8M per year.
- Biofourmis's estimated revenue per employee is $217,000
- Biofourmis's total funding is $463.6M.
- Biofourmis's current valuation is $1.3B. (April 2022)
Employee Data
- Biofourmis has 543 Employees.
- Biofourmis grew their employee count by -27% last year.
Biofourmis's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder & CEO | Reveal Email/Phone |
2 | Founder and CEO | Reveal Email/Phone |
3 | CTO | Reveal Email/Phone |
4 | General Manager, Country Head (Asia) VP Clinical Trial and Commercial Operations | Reveal Email/Phone |
5 | COO | Reveal Email/Phone |
6 | CFO | Reveal Email/Phone |
7 | VP Product Management | Reveal Email/Phone |
8 | VP Marketing | Reveal Email/Phone |
9 | VP - Strategic Accounts (Decentralized/Digital Clinical Trials) | Reveal Email/Phone |
10 | VP Sales, Health Systems | Reveal Email/Phone |
Biofourmis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $31800M | 109578 | 4% | $367M | $146B |
What Is Biofourmis?
Biofourmis is a fast-growing global health IT start-up founded in Singapore that augments personalized patient care and therapies with Digital Therapeutics for better management of patients with complex chronic conditions. The company discovers, develops and delivers clinically validated software-based therapeutics to enable better outcomes for patients. These solutions include advanced tools for clinicians to deliver personalized care and cost-effective solutions for payers. Biofourmis has built Biovitals?, a highly sophisticated personalized artificial intelligence (AI)-powered health analytics platform that predicts clinical exacerbation days in advance before a critical event. Biovitals? is the backbone of the company?s Digital Therapeutics product pipeline, which spans a number of therapeutic areas and disease states, including heart failure, acute coronary syndrome, COPD and chronic pain.
keywords:Medical Devices
$463.6M
Total Funding
543
Number of Employees
$117.8M
Revenue (est)
-27%
Employee Growth %
$1.3B
Valuation
N/A
Accelerator
Biofourmis News
Biofourmis solutions instead use a blend of passive inputs via continuous monitoring devices, active inputs from episodic monitoring devices,...
Biofourmis also plans to fund more clinical trials and improve its digital therapeutic (DTx). Its goal is to forge stronger partnerships with...
Earlier this year the company expanded its artificial intelligence-based virtual care service to monitor complex chronic conditions. The new...
BOSTON, Dec. 3, 2020 /PRNewswire/ -- Biofourmis, a Boston-based global leader in digital therapeutics and virtual care that powers personalized predictive care, announces the national rollout of Biovitals® [email protected]TM—an artificial intelligence-based, turnkey technology platform that e ...
As reported by Catherine Shu, TechCrunch (found here) Biofourmis, which combines AI-based data analytics and biosensors to monitor the progress of medical treatments, has raised funding from one of the world’s most high-profile investors. The digital therapeutics company, which launched in Sing ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $102.7M | 543 | 14% | $1.3B |
#2 | $68.1M | 545 | 7% | N/A |
#3 | $102.2M | 545 | -2% | N/A |
#4 | $68.3M | 546 | 10% | N/A |
#5 | $100.9M | 548 | 4% | $4.5M |